Largest Phase 3 Trial of Psilocybin for Depression Has Begun | Psychedelic spotlight

psilocybin for depression

As our social fabric is unraveling and rates of depression continue to rise, affecting an estimated 310 million people worldwide, psilocybin research has given us a glimmer of hope that things may be changing for the better. The largest Phase 3 clinical trial investigating the safety, efficacy, and tolerability of psilocybin as a treatment for … Read more

Vistagen to Present Exploratory Safety and Efficacy Data for Fasedienol (PH94B) from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting

Vistagen to Present Exploratory Safety and Efficacy Data for Fasedienol (PH94B) from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting

Last Hour Poster Presentation Highlights Data on Long-Term Open-Label Treatment of As-Needed Intranasal Phasedienol Administrations in a Real-World Setting SOUTH SAN FRANCISCO, California, May 30, 2023–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), an advanced clinical-stage biopharmaceutical company aiming to transform the treatment landscape for people living with anxiety, depression, and other central nervous system (CNS) disorders, today announced … Read more